ESMO Open

Article	Citations
Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines☆	199
Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers	113
Adolescents and young adults (AYA) with cancer: a position paper from the AYA Working Group of the European Society for Medical Oncology (ESMO) and the European Society for Paediatric Oncology (SIOPE)	107
Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN	102
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update	87
Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials	86
Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies	78
The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of rando	77
The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?	77
Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era	76
Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment	75
Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations	72
Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment	69
Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts	69
The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM–SIAPEC-IAP–SIBioC–SIC–SIF Italian Scientific Societies	69
Prospective experimental treatment of colorectal cancer patients based on organoid drug responses	63
Decline and incomplete recovery in cancer diagnoses during the COVID-19 pandemic in Belgium: a year-long, population-level analysis	60
A prospective cohort study on the safety of checkpoint inhibitors in older cancer patients – the ELDERS study	59
Care of the adult cancer patient at the end of life: ESMO Clinical Practice Guidelines	57
Artificial intelligence for detection of microsatellite instability in colorectal cancer—a multicentric analysis of a pre-screening tool for clinical application	53
Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort	51
Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer	51
Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in France	49
Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer	48
How I treat biliary tract cancer	48

Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis	47
Discordance between immunochemistry of mismatch repair proteins and molecular testing of microsatellite instability in colorectal cancer	46
Targeting immunoliposomes to EGFR-positive glioblastoma	45
The impact of COVID-19 on oncology professionals: results of the ESMO Resilience Task Force survey collaboration	45
How to use liquid biopsies to treat patients with cancer	41
Strategies to tackle RAS-mutated metastatic colorectal cancer	40
Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer	40
Salivary gland cancer: ESMO–European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up	39
The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer	39
Sex-based differences in response to anti-PD-1 or PD-L1 treatment in patients with non-small-cell lung cancer expressing high PD-L1 levels. A systematic review and meta-analysis of randomized clinical	39
Osimertinib plus platinum–pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study	39
Worldwide cancer statistics of adolescents and young adults in 2019: a systematic analysis of the Global Burden of Disease Study 2019	38
Serologic response to COVID-19 infection and/or vaccine in cancer patients on active treatment	38
Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review	38
Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge	38
Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapy	37
How we treat primary central nervous system lymphoma	37
Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer	36
Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer	35
First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts	35
Lymphovascular invasion has a significant prognostic impact in patients with early breast cancer, results from a large, national, multicenter, retrospective cohort study	35
Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring	35
Efficacy and activity of PD-1 blockade in patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis with focus on the value of PD-L1 combined positive score	34
A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study	34
Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort	34
Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trials	33
Rethinking prognostic factors in locally advanced or metastatic urothelial carcinoma in the immune checkpoint blockade era: a multicenter retrospective study	33
Consensus for HER2 alterations testing in non-small-cell lung cancer	33
How we treat endocrine complications of immune checkpoint inhibitors	33
Impact of the COVID-19 pandemic on the care of cancer patients in Spain	32
Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus	32
Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody–drug conjugates in the breast cancer treatment landscape	31
Immune checkpoint inhibitor administration during pregnancy: a case series	30
Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival	30
Pan-Asian adaptation of the EHNS–ESMO–ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck	30
Anti-TIGIT therapies for solid tumors: a systematic review	30
Supportive care in patients with cancer during the COVID-19 pandemic	30
The EMA assessment of pembrolizumab as monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer	29
HPV ctDNA detection of high-risk HPV types during chemoradiotherapy for locally advanced cervical cancer	29
Phase I/II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma (ITCC-050)☆	29
Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario	29
Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies	29
Checkpoint inhibitors, fertility, pregnancy, and sexual life: a systematic review	28
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients	28
Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancer	27
Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies	27
Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up	27
Issues and limitations of available biomarkers for fluoropyrimidine-based chemotherapy toxicity, a narrative review of the literature	27
Survival after neoadjuvant therapy with trastuzumab–lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials	27
Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program	27

How we treat patients with metastatic HER2-positive breast cancer	27
Recurrent or primary metastatic cervical cancer: current and future treatments	27
A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903	26
Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy	26
Efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasms	25
Pembrolizumab versus chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial in Asia	25
Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States	25
The impact of COVID-19 on oncology professionals—one year on: lessons learned from the ESMO Resilience Task Force survey series	24
The impact of COVID-19 on cancer care and oncology clinical research: an experts’ perspective	24
Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 3	24
Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial	24
Immune cell engagers in solid tumors: promises and challenges of the next generation immunotherapy	23
How we treat HER2-positive brain metastases	23
Identification of cell surface targets for CAR-T cell therapies and antibody–drug conjugates in breast cancer	23
Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib	22
Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup study	22
The prognostic and predictive impact of low estrogen receptor expression in early breast cancer: a systematic review and meta-analysis	22
Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases in a large real-life database	22
Squamous rectal carcinoma: a rare malignancy, literature review and management recommendations	22
First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an International Expert Panel Meeting by the Italian Association of Thoracic Oncolog	21
Knowledge, attitudes and practices related to the COVID-19 outbreak among Romanian adults with cancer: a cross-sectional national survey	21
Sex and gender perspectives in colorectal cancer	21
European Reference Network for rare adult solid cancers, statement and integration to health care systems of member states: a position paper of the ERN EURACAN	21
Capecitabine plus temozolomide in patients with grade 3 unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms with Ki-67 index <55%: single-arm phase II study	21
First-line immune checkpoint inhibitors for extensive stage small-cell lung cancer: clinical developments and future directions	21
Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase II study	21
Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer	21
Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: a systematic review and meta-analysis of randomized trials	21
Circulating miR-30b-5p levels in plasma as a novel potential biomarker for early detection of breast cancer	20
Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards	20
Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer	20
The concerns of oncology professionals during the COVID-19 pandemic: results from the ESMO Resilience Task Force survey II	20
A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202)	20
Clinical features of patients with HER2-positive breast cancer and development of a nomogram for predicting survival	20
Breast cancer in very young women—a multicenter 10-year experience	20
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort	20
Early prediction of pancreatic cancer from new-onset diabetes: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Endocrinologia (SIE)/Società Ital	20
Has COVID-19 had a greater impact on female than male oncologists? Results of the ESMO Women for Oncology (W4O) Survey	19
Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Canc	19
Expert opinion on management of pancreatic exocrine insufficiency in pancreatic cancer	19
Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis	19
Small-cell lung cancer in never-smokers	19
Increased risk of diabetes in cancer survivors: a pooled analysis of 13 population-based cohort studies	19
Beta-blockers in early-stage breast cancer: a systematic review and meta-analysis	19
Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS)	19
Cell-free DNA from bile outperformed plasma as a potential alternative to tissue biopsy in biliary tract cancer	19
Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A	19
Distribution of the workforce involved in cancer care: a systematic review of the literature	18
Novel molecular targeted therapies for patients with neurofibromatosis type 1 with inoperable plexiform neurofibromas: a comprehensive review	18
Role of surgery and hyperthermic intraperitoneal chemotherapy in ovarian cancer	18
Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics study	18
The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022	18
Neoadjuvant chemotherapy with or without radiotherapy versus upfront surgery for resectable pancreatic adenocarcinoma: a meta-analysis of randomized clinical trials	18
Vaccination against Her-2/neu, with focus on peptide-based vaccines	18
Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer	17
Prognostic value of tumor mutational burden in patients with oral cavity squamous cell carcinoma treated with upfront surgery	17
Anxiety and depression in adult cancer patients: ESMO Clinical Practice Guideline	17
Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours	17
Real-world circulating tumor DNA analysis depicts resistance mechanism and clonal evolution in ALK inhibitor-treated lung adenocarcinoma patients	17
Clinical implications of isolated troponinemia following immune checkpoint inhibitor therapy	17
The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma	17
A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgery	17
Role of molecular genetics in the clinical management of cholangiocarcinoma	17
Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational coho	16
The European Medicines Agency review of entrectinib for the treatment of adult or paediatric patients with solid tumours who have a neurotrophic tyrosine receptor kinase gene fusions and adult patient	16
COVID-19 in patients with cancer: first report of the ESMO international, registry-based, cohort study (ESMO-CoCARE)	16
Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors	16
Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study	16
Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial	16
MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAF metastatic colorectal cancer	16
Genomic profiling in non-small-cell lung cancer in young patients. A systematic review	16
Immunological inflammatory biomarkers as prognostic predictors for advanced hepatocellular carcinoma	16
A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer	16
Systematic review and meta-analysis of post-progression outcomes in ER+/HER2− metastatic breast cancer after CDK4/6 inhibitors within randomized clinical trials	16
The impact of the multidisciplinary tumor board (MDTB) on the management of pancreatic diseases in a tertiary referral center	16
PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers	15
How I treat stage II colon cancer patients	15
Social distress among medical oncologists and other healthcare professionals during the first wave of COVID-19 pandemic in Italy	15
Emerging targets for anticancer vaccination: PD-1	15
Gefitinib induction followed by chemoradiotherapy in EGFR-mutant, locally advanced non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study	15

How to read a next-generation sequencing report—what oncologists need to know	15
Twelve years of European cancer drug approval—a systematic investigation of the ‘magnitude of clinical benefit’	15
Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients	15
Assessment of the albumin-bilirubin grade as a prognostic factor in patients with non-small-cell lung cancer receiving anti-PD-1-based therapy	15
IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer	15
Targeting KRASG12C in colorectal cancer: the beginning of a new era	15
Risk for stroke and myocardial infarction with abiraterone versus enzalutamide in metastatic prostate cancer patients	15
Flexible care in breast cancer	15
Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME)	15
The DNA damage response network in the treatment of head and neck squamous cell carcinoma	15
Emerging targets for anticancer vaccination: IDH	15
Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study)	15
A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma☆	15
How I perform fertility preservation in breast cancer patients	14
Impact of deep learning-determined smoking status on mortality of cancer patients: never too late to quit	14
Impact of COVID-19 on social media as perceived by the oncology community: results from a survey in collaboration with the European Society for Medical Oncology (ESMO) and the OncoAlert Network	14
Liquid biopsy by combining 5-hydroxymethylcytosine signatures of plasma cell-free DNA and protein biomarkers for diagnosis and prognosis of hepatocellular carcinoma	14
Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe	14
Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer	14
Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study	14
Refining patient selection for breast cancer immunotherapy: beyond PD-L1	14
Immune-related adverse events as potential surrogates of immune checkpoint inhibitors’ efficacy: a systematic review and meta-analysis of randomized studies	14
CDK4/6 inhibitors as adjuvant treatment for hormone receptor-positive, HER2-negative early breast cancer: a systematic review and meta-analysis	14
Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101	14
Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study	14
Major adverse cardiovascular events associated with VEGF-targeted anticancer tyrosine kinase inhibitors: a real-life study and proposed algorithm for proactive management	14
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma	14
High BRAF variant allele frequencies are associated with distinct pathological features and responsiveness to target therapy in melanoma patients	13
Identifying and preventing burnout in young oncologists, an overwhelming challenge in the COVID-19 era: a study of the Spanish Society of Medical Oncology (SEOM)	13
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study	13
Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial	13
Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an upda	13
High body mass index and pre-existing autoimmune disease are associated with an increased risk of immune-related adverse events in cancer patients treated with PD-(L)1 inhibitors across different soli	13
Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials	13
Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalut	13
Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-	13
Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs	13
Efficacy of tyrosine kinase inhibitors for the treatment of patients with HER2-positive breast cancer with brain metastases: a systematic review and meta-analysis	13
Clinical utility of comprehensive circulating tumor DNA genotyping compared with standard of care tissue testing in patients with newly diagnosed metastatic colorectal cancer	12
Targeting HER3 for cancer treatment: a new horizon for an old target	12
Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern	12
Organized breast cancer screening not only reduces mortality from breast cancer but also significantly decreases disability-adjusted life years: analysis of the Global Burden of Disease Study and scre	12
Rationale and study design of the CHIPPI-1808 trial: a phase III randomized clinical trial evaluating hyperthermic intraperitoneal chemotherapy (HIPEC) for stage III ovarian cancer patients treated wi	12
Poly(ADP-ribose) polymerase inhibitor-associated myelodysplastic syndrome/acute myeloid leukemia: a pharmacovigilance analysis of the FAERS database	12
Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors	12
Tumor mutational burden and immune infiltrates in renal cell carcinoma and matched brain metastases	12
Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma	12
Rethinking treatment for RET-altered lung and thyroid cancers: selpercatinib approval by the EMA	12
Antineoplastic dosing in overweight and obese cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Endocrinologia (SIE)/Società Ital	12
Varlitinib plus capecitabine in second-line advanced biliary tract cancer: a randomized, phase II study (TreeTopp)	12
COVID-19 risk for patients undergoing anticancer treatment at the outpatient clinic of the National Cancer Institute of Milan: the COVINT study	12
Molecular profiling of Asian patients with advanced melanoma receiving check-point inhibitor treatment	12
The age-related impact of surviving sarcoma on health-related quality of life: data from the SURVSARC study	12
Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey	12
Metronomic oral vinorelbine in previously untreated advanced non-small-cell lung cancer patients unfit for platinum-based chemotherapy: results of the randomized phase II Tempo Lung trial	11
Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma?	11
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer	11
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic r	11
Standard versus personalized schedule of regorafenib in metastatic gastrointestinal stromal tumors: a retrospective, multicenter, real-world study	11
Systemic treatment of advanced clear cell sarcoma: results from a retrospective international series from the World Sarcoma Network	11
How we identify and treat neuromuscular toxicity induced by immune checkpoint inhibitors	11
Clinical and molecular practice of European thoracic pathology laboratories during the COVID-19 pandemic. The past and the near future	11
Beyond the lessons learned from the COVID-19 pandemic: opportunities to optimize clinical trial implementation in oncology	11
Does neoadjuvant treatment in resectable pancreatic cancer improve overall survival? A systematic review and meta-analysis of randomized controlled trials	11
Clinical prognostic factors in advanced epithelioid haemangioendothelioma: a retrospective case series analysis within the Italian Rare Cancers Network	11
Cancer diagnosis in Catalonia (Spain) after two years of COVID-19 pandemic: an incomplete recovery	11
ctDNA as a biomarker of progression in oesophageal adenocarcinoma	11
Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7	11
Macrophage and monocyte subsets as new therapeutic targets in cancer immunotherapy	11
Lack of prognostic impact of sentinel node micro-metastases in endocrine receptor-positive early breast cancer: results from a large multicenter cohort☆	11
Cancer burden in adolescents and young adults in Europe	11
Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate	11
Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications	11
Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study	11
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer	11
Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon?	11
The efficacy of immune checkpoint inhibitors in elderly patients: a meta-analysis and meta-regression	11
Addition of androgen receptor-targeted agents to androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis	11
Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study	11
Longitudinal characterisation of haematological and biochemical parameters in cancer patients prior to and during COVID-19 reveals features associated with outcome	11
How we treat locoregional melanoma	11
Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial	11
Association of improved overall survival with decreased distant metastasis following asparaginase-based chemotherapy and radiotherapy for intermediate- and high-risk early-stage extranodal nasal-type	10
Safety and efficacy of dendritic cell-based immunotherapy (DCVAC/LuCa) combined with carboplatin/pemetrexed for patients with advanced non-squamous non-small-cell lung cancer without oncogenic drivers	10
Safety and activity of alectinib plus bevacizumab in patients with advanced ALK-rearranged non-small-cell lung cancer: a phase I/II study	10
Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review	10
The systemic pro-inflammatory response: targeting the dangerous liaison between COVID-19 and cancer	10
Site-specific therapy in cancers of unknown primary site: a systematic review and meta-analysis	10
Advances in the systemic treatment of therapeutic approaches in biliary tract cancer	10
Association of differential expression of immunoregulatory molecules and presence of targetable mutations may inform rational design of clinical trials	10
Multimodal survival prediction in advanced pancreatic cancer using machine learning	10
Combining immunotherapy with an epidrug in squamous cell carcinomas of different locations: rationale and design of the PEVO basket trial	10
How we treat medulloblastoma in adults	10
The current role of precision surgery in oligometastatic prostate cancer	10
Clinical management of patients with thymic epithelial tumors: the recommendations endorsed by the Italian Association of Medical Oncology (AIOM)	10